Azathioprine: Specific Genotype Linked to Treatment Discontinuation Due to Toxicity
source: pixabay.com

Azathioprine: Specific Genotype Linked to Treatment Discontinuation Due to Toxicity

According to a story from Medpage Today, patients using the drug azathioprine who carried a certain genotype were three times more likely to need to either cease treatment or reduce…

Continue Reading Azathioprine: Specific Genotype Linked to Treatment Discontinuation Due to Toxicity
Study Shows GPA and Tuberculosis Might Have Similar Features
kalhh / Pixabay

Study Shows GPA and Tuberculosis Might Have Similar Features

According to a recent article, a new study shows that granulomatosis with polyangiitis (GPA) and tuberculosis might have shared features, making diagnosis more difficult. Granulomatosis with Polyangiitis (GPA) Granulomatosis with…

Continue Reading Study Shows GPA and Tuberculosis Might Have Similar Features

Study Determined Symptom Prevalence Amongst Subtypes of AAVs

A recent study has examined the characteristics and the clinical outcomes for individuals with severe anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs). AAVs are a very rare group of systemic autoimmune conditions.…

Continue Reading Study Determined Symptom Prevalence Amongst Subtypes of AAVs
TAVNEOS Approved in Japan for ANCA-Associated Vasculitis
Source: https://unsplash.com/photos/ZHys6xN7sUE

TAVNEOS Approved in Japan for ANCA-Associated Vasculitis

Sometimes, certain drugs may be approved in different countries and not in others. However, drug approval spanning multiple countries highlights the importance of getting drugs and treatments into the hands…

Continue Reading TAVNEOS Approved in Japan for ANCA-Associated Vasculitis
Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study
source: pixabay.com

Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study

Nucala and Corticosteroids Can Increase EGPA Remission

Recently, researchers sought to examine how Nucala (mepolizumab) affected disease progression in patients with eosinophilic granulomatosis with polyangiitis (EGPA), especially when used in conjunction with corticosteroids. According to ANCA Vasculitis…

Continue Reading Nucala and Corticosteroids Can Increase EGPA Remission
Study Finds Thrombosis May be the First Sign of Granulomatosis with Polyangiitis
source: pixabay.com

Study Finds Thrombosis May be the First Sign of Granulomatosis with Polyangiitis

A recent study has found that thrombosis may be the first manifestation of granulomatosis with polyangiitis disease in children following the very first report of its presentation in a 13…

Continue Reading Study Finds Thrombosis May be the First Sign of Granulomatosis with Polyangiitis

Researchers Find Hypothyroidism is Linked to ANCA-Associated Vasculitis

The American College of Rheumatology presented new findings on November 5, 2020 at their virtual conference. They found that in patients with ANCA-associated vasculitis (AAV), hypothyroidism is associated with positive…

Continue Reading Researchers Find Hypothyroidism is Linked to ANCA-Associated Vasculitis
Avacopan Better than Prednisone for Patients with AAV, Study Shares
freegr / Pixabay

Avacopan Better than Prednisone for Patients with AAV, Study Shares

Recently, the American College of Rheumatology (ACR) virtually held ACR Convergence 2020, the organization's annual meeting. At the meeting, researchers shared new insights in the realm of rheumatology; these were…

Continue Reading Avacopan Better than Prednisone for Patients with AAV, Study Shares
The FDA Approves First Pediatric Treatment for Rare Forms of Vasculitis
qimono / Pixabay

The FDA Approves First Pediatric Treatment for Rare Forms of Vasculitis

According to a story from finanzen.ch, the US Food and Drug Administration (FDA) recently approved the drug rituximab (marketed as Rituxan) as a treatment in child patients aged at least…

Continue Reading The FDA Approves First Pediatric Treatment for Rare Forms of Vasculitis